SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hjelm M)
 

Sökning: WFRF:(Hjelm M) > Serum proteomic pro...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008084naa a2200721 4500
001oai:DiVA.org:oru-87457
003SwePub
008201119s2021 | |||||||||||000 ||eng|
009oai:DiVA.org:liu-176483
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-874572 URI
0247 a https://doi.org/10.1093/ecco-jcc/jjaa2302 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1764832 URI
040 a (SwePub)orud (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Kalla, R.u Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom; MRC Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh, United Kingdom,Univ Edinburgh, Scotland; Univ Edinburgh, Scotland4 aut
2451 0a Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease
264 c 2020-11-17
264 1b Elsevier,c 2021
338 a print2 rdacarrier
500 a Funding Agencies|EU FP7 grant: IBD-CHARACTER [2858546]; Wellcome TrustWellcome TrustEuropean Commission
520 a BACKGROUND: Success in personalised medicine in complex disease is critically dependent on biomarker discovery. We profiled serum proteins using a novel proximity extension assay (PEA) to identify diagnostic and prognostic biomarkers in inflammatory bowel disease (IBD).METHODS: We conducted a prospective case-control study in an inception cohort of 552 patients (328 IBD, 224 non-IBD), profiling proteins recruited across 6 centres. Treatment escalation was characterised by the need for biological agents or surgery after initial disease remission. Nested leave-one-out cross validation was used to examine the performance of diagnostic and prognostic proteins.RESULTS: A total of 66 serum proteins differentiated IBD from symptomatic non-IBD controls including MMP-12 (Holm adjusted p=4.1×10 -23 ) and OSM (p=3.7×10 -16). Nine of these proteins associate with cis- germline variation (59 independent SNPs). Fifteen proteins, all members of TNF independent pathways including IL-1 and OSM predicted escalation, over a median follow-up of 518 (IQR 224-756) days. Nested cross-validation of the entire data set allows characterisation of 5-protein-models (96% comprising five core proteins ITGAV, EpCAM, IL18, SLAMF7, and IL8) which define a high-risk subgroup in IBD (HR 3.90, CI: 2.43-6.26), or allows distinct 2, and 3 protein models for UC and CD respectively.CONCLUSION: We have characterised a simple oligo-protein panel that has the potential to identify IBD from symptomatic controls and to predict future disease course. Further prospective work is required to validate our findings.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng
653 a Crohn's disease
653 a OSM
653 a genetics
653 a inflammatory bowel diseases (IBD)
653 a outcomes
653 a prognosis
653 a protein quantitative trait loci
653 a proteins
653 a proximity extension assay
653 a ulcerative colitis
7001 a Adams, A. T.u Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom; Translational Gastroenterology Unit, Nuffield Department of Medicine, Experimental Medicine Division, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom,Univ Edinburgh, Scotland; Univ Oxford, England4 aut
7001 a Bergemalm, Daniel,d 1977-u Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Gastroenterology,Orebro Univ, Sweden4 aut0 (Swepub:oru)dbm
7001 a Vatn, S.u Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway,Akershus Univ Hosp, Norway4 aut
7001 a Kennedy, N. A.u Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom; Exeter IBD and Pharmacogenetics group, University of Exeter, United Kingdom,Univ Edinburgh, Scotland; Univ Exeter, England4 aut
7001 a Ricanek, P.u Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway,Univ Edinburgh, Scotland; Univ Oslo, Norway4 aut
7001 a Lindstrom, J.u Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway,Akershus Univ Hosp, Norway; Univ Oslo, Norway4 aut
7001 a Ocklind, A.u Olink Proteomics, Uppsala, Sweden,Olink Prote, Sweden4 aut
7001 a Hjelm, F.u Olink Proteomics, Uppsala, Sweden,Olink Prote, Sweden4 aut
7001 a Ventham, N. T.u Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom,Univ Edinburgh, Scotland4 aut
7001 a Ho, G. T.u MRC Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh, United Kingdom,Univ Edinburgh, Scotland4 aut
7001 a Petren, C.u Olink Proteomics, Uppsala, Sweden,Olink Prote, Sweden4 aut
7001 a Repsilber, Dirk,d 1971-u Örebro universitet,Institutionen för medicinska vetenskaper,Orebro Univ, Sweden4 aut0 (Swepub:oru)drr
7001 a Söderholm, Johan Du Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Kirurgiska kliniken US4 aut0 (Swepub:liu)sodda63
7001 a Pierik, M.u Maastricht University Medical Centre (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands,Maastricht Univ Med Ctr MUMC, Netherlands4 aut
7001 a D'Amato, M.u Biocruces Health Research Institute, Molecular Genetics of Digestive Diseases, Cruces, Bilbao, Spain; School of Biological Sciences, Monash University, Victoria, Australia,Basque Fdn Sci, Spain; Basque Fdn Sci, Spain; Monash Univ, Australia4 aut
7001 a Gomollón, F.u HCU "Lozano Blesa," IIS Aragón, Zaragoza, Spain4 aut
7001 a Olbjorn, C.u Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway,Akershus Univ Hosp, Norway; Univ Oslo, Norway4 aut
7001 a Jahnsen, J.u Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway,Akershus Univ Hosp, Norway; Univ Oslo, Norway,Orebro Univ, Sweden,Univ Edinburgh, Scotland; Univ Oxford, England4 aut
7001 a Vatn, M. H.u Department of Gastroenterology, Akershus UnInstitute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway,Univ Oslo, Norway4 aut
7001 a Halfvarson, Jonas,d 1970-u Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology4 aut0 (Swepub:oru)jshn
7001 a Satsangi, J.u Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom; Translational Gastroenterology Unit, Nuffield Department of Medicine, Experimental Medicine Division, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom4 aut
7102 a Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom; MRC Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh, United Kingdomb Univ Edinburgh, Scotland; Univ Edinburgh, Scotland4 org
7730 t Journal of Crohn's & Colitisd : Elsevierg 15:5, s. 699-708q 15:5<699-708x 1873-9946x 1876-4479
8564 u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095384
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-87457
8564 8u https://doi.org/10.1093/ecco-jcc/jjaa230
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-176483

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy